Source link : https://www.newshealth.biz/health-news/novel-cardiac-myosin-inhibitor-improves-exercise-capacity-in-hcm/
The novel cardiac myosin inhibitor aficamten improved peak oxygen uptake in symptomatic obstructive hypertrophic cardiomyopathy (HCM), the pivotal SEQUOIA-HCM trial showed. At 24 weeks, the mean change in the peak oxygen uptake was 1.8 mL/kg/min with the drug compared with no change in the placebo group (P
Author : News Health
Publish date : 2024-05-13 14:15:16
Copyright for syndicated content belongs to the linked Source.
in Health